FDA_Warning_Letters, Import_Alerts_&_EU_Non-Compliances_in_2019
X

Find Drugs for Infections and Infectious Diseases in Phase I Clinical Development in UNITED STATES

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Curcumin

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 17, 2020

            Details:

            Lipocurc has advantage of not only safely suppressing interleukin-6 by 83%, it also profoundly suppresses TNF-alpha by 77% and IL-1 beta by 85% as well as suppressing RANTES, IL-8, MCP-1& MIP-alpha.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA-1273

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 16, 2020

            Details:

            The Phase 1 study is evaluating the safety and immunogenicity of three dose levels of mRNA-1273 (25, 100, 250 ?g) administered on a two-dose vaccination schedule, given 28 days apart.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Amniotic fluid supplement

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 13, 2020

            Details:

            Company plans to evaluate its amniotic fluid concentrate, AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Vesatolimod

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 10, 2020

            Details:

            Results presented at CROI 2020 support further evaluation of vesatolimod as part of investigational curative regimens aimed at achieving ART-Free control of HIV.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): 3BNC117,10-1074

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Rockefeller University

            Deal Size: Undisclosed Upfront Cash: $1.7 million

            Deal Type: Collaboration March 03, 2020

            Details:

            Celldex utilized their internal capabilities in production cell line development, process development and GMP manufacturing to support clinical development of 3BNC117 and 10-1074.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): INO-4800

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 03, 2020

            Details:

            Using their modern DNA medicines platform, inovio designed its DNA vaccine INO-4800 in three hours after the publication of the genetic sequence of the novel coronavirus that causes COVID-19.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): PLG0206

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: CARB-X

            Deal Size: $12.1 million Upfront Cash: Undisclosed

            Deal Type: Funding February 25, 2020

            Details:

            The funding will help Peptilogics to advance its PLG0206 through Phase 1 clinical studies for its first indication of prosthetic joint infections (PJI).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mRNA-1273

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            Details:

            mRNA-1273 delivered from Company’s cGMP facility in 42 days from sequence selection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-2173

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            Details:

            The patent covered covering the composition of matter and methods of use for ATI-2173.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ATI-2173

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 12, 2020

            Details:

            The Phase Ia study is a randomized, double-blind, placebo-controlled single-ascending dose study in healthy volunteers to evaluate the ATI-2173's safety, tolerability and pharmacokinetic profile.

            PharmaCompass